Drug Topics April 4, 2024
Lauren Biscaldi, MS, Managing Editor

The FDA has approved iloperidone tablets (Fanapt) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. The atypical antipsychotic agent was initially approved in 2009 for the acute treatment of schizophrenia.1

Bipolar disorder affects approximately 2.8% of adults in the United States; 83% of these cases are considered severe. Bipolar I disorder with manic or mixed episodes comprise a subset of the approximately 10 million Americans living with the disease.

“Many patients are still unable to find suitable treatment options for effectively managing bipolar disorder,” said Stephen Stahl, MD, PhD, professor of psychiatry at the University of California San Diego, in a press release.1 “Tailoring the right treatment for the right patient is...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article